Round voting button logo

HB1292

Expanding the right to try act to include certain qualifying severe illness and permitting certain regenerative stem cell therapies under the act.

Introduced·12/1/25
Text Text

Expands the Right to Try Act to include certain severe illnesses and regenerative stem cell therapies.

New Hampshire HB1292 expands the Right to Try Act to include patients with certain severe illnesses and permits regenerative stem cell therapies. The bill allows eligible patients with terminal or qualifying severe illnesses to access investigational drugs, biologics, or devices not yet approved by the FDA. It also permits physicians to perform stem cell therapies for orthopedics, wound care, or pain management, provided certain conditions are met. The bill aims to foster medical innovation while ensuring ethical standards are upheld.

Included in complete analysis

  • Overview
  • Core Provisions
  • Implementation
  • Impact
  • Legal Framework
  • Critical Issues

See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.

Where it stands

Current
In committee
Next
Committee decision

Sponsors

0
10
RRRRRRRRRR
Democratic CaucusRepublican Caucus

Calendar

Feb 13

10:00 AM

Judiciary Executive Session

Feb 11

1:00 PM

Judiciary Public Hearing

History

Mar 5

House

Refer for Interim Study: Motion Adopted Voice Vote 03/05/2026 House Journal 6 P. 24

Feb 26

House

Committee Report: Refer for Interim Study 02/13/2026 (Vote 17-1; Consent Calendar) House Calendar 9 P. 18

Feb 5

House

Public Hearing: 02/11/2026 01:00 pm GP 230